Status: Recruiting
A Study of CAR T-Cells in Relapsed/Refractory Hematologic Malignancy
This study is a single-center, open-label clinical trial of single-dose of CAR T-cells in subjects with relapsed/refractory hematologic malignancy.
Participants needed: 9
Trial details
Phase: Early Phase 1Age: 18-70Biological sex: AllType: InterventionalSponsor: Affiliated Hospital of Nantong UniversityUpdated: Jan 3, 2025Locations: 1
Eligibility criteria
Voluntarily participate in the clinical study. The individual or the legal guard... [+32]
CNS-3 disease is defined as detectable tumor cells in the cerebrospinal fluid (C... [+33]